Cano Health Analyst Ratings
Cano Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | -56.33% | UBS | $12 → $3.75 | Downgrades | Neutral → Sell |
| 08/14/2023 | -94.18% | Credit Suisse | $2.5 → $0.5 | Maintains | Neutral |
| 08/11/2023 | — | Jefferies | Downgrades | Buy → Hold | |
| 08/11/2023 | -90.68% | Citigroup | $4 → $0.8 | Downgrades | Buy → Neutral |
| 05/16/2023 | -88.36% | Piper Sandler | $0.5 → $1 | Maintains | Underweight |
| 05/12/2023 | -70.89% | Credit Suisse | → $2.5 | Reiterates | Neutral → Neutral |
| 01/06/2023 | -85.44% | UBS | $12 → $1.25 | Downgrades | Buy → Neutral |
| 01/05/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/13/2022 | -82.53% | B of A Securities | → $1.5 | Reinstates | → Underperform |
| 11/16/2022 | -41.78% | Citigroup | $7 → $5 | Maintains | Buy |
| 11/10/2022 | -65.07% | Cowen & Co. | $10 → $3 | Downgrades | Outperform → Market Perform |
| 11/10/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 10/27/2022 | -41.78% | Credit Suisse | $10 → $5 | Downgrades | Outperform → Neutral |
| 09/07/2022 | -18.49% | Truist Securities | → $7 | Initiates Coverage On | → Hold |
| 08/10/2022 | -53.42% | Piper Sandler | $4 → $4 | Maintains | Underweight |
| 06/24/2022 | -6.84% | Raymond James | → $8 | Initiates Coverage On | → Outperform |
| 06/15/2022 | -30.13% | B of A Securities | $8 → $6 | Downgrades | Buy → Neutral |
| 05/11/2022 | 16.45% | Credit Suisse | $13 → $10 | Maintains | Outperform |
| 05/11/2022 | -53.42% | Piper Sandler | $5 → $4 | Maintains | Underweight |
| 05/10/2022 | -6.84% | Citigroup | $10 → $8 | Maintains | Buy |
| 05/03/2022 | -6.84% | B of A Securities | → $8 | Initiates Coverage On | → Buy |
| 04/20/2022 | 74.67% | UBS | → $15 | Initiates Coverage On | → Buy |
| 04/06/2022 | -41.78% | Piper Sandler | $8.5 → $5 | Downgrades | Neutral → Underweight |
| 03/16/2022 | 51.38% | Credit Suisse | $15 → $13 | Maintains | Outperform |
| 11/10/2021 | 51.38% | Piper Sandler | $11 → $13 | Maintains | Neutral |
| 10/20/2021 | 97.96% | Jefferies | → $17 | Initiates Coverage On | → Buy |
| 10/19/2021 | 28.09% | Piper Sandler | → $11 | Initiates Coverage On | → Neutral |
| 10/01/2021 | 121.25% | Wolfe Research | → $19 | Initiates Coverage On | → Outperform |
| 09/21/2021 | 132.89% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 09/10/2021 | 109.6% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
| 08/02/2021 | 109.6% | Credit Suisse | → $18 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/17/2023 | -56.33% | 瑞銀（UBS） | 12 美元 → 3.75 美元 | 降級 | 中性 → 賣出 |
| 08/14/2023 | -94.18% | 瑞士信貸 | 2.5 美元 → 0.5 美元 | 維護 | 中立 |
| 08/11/2023 | — | 傑富瑞集團 | 降級 | 買入 → 持有 | |
| 08/11/2023 | -90.68% | 花旗集團 | 4 美元 → 0.8 美元 | 降級 | 買入 → 中性 |
| 05/16/2023 | -88.36% | 派珀·桑德勒 | 0.5 美元 → 1 美元 | 維護 | 體重不足 |
| 05/12/2023 | -70.89% | 瑞士信貸 | → 2.5 美元 | 重申 | 中性 → 中性 |
| 01/06/2023 | -85.44% | 瑞銀（UBS） | 12 美元 → 1.25 美元 | 降級 | 買入 → 中性 |
| 01/05/2023 | — | 沃爾夫研究 | 降級 | 跑贏大盤 → 同行表現 | |
| 12/13/2022 | -82.53% | B of A 類證券 | → 1.5 美元 | 恢復 | → 表現不佳 |
| 11/16/2022 | -41.78% | 花旗集團 | 7 美元 → 5 美元 | 維護 | 買 |
| 2022 年 10 月 11 日 | -65.07% | Cowen & Co. | 10 美元 → 3 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 2022 年 10 月 11 日 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
| 10/27/2022 | -41.78% | 瑞士信貸 | 10 美元 → 5 美元 | 降級 | 跑贏大盤 → 中性 |
| 09/07/2022 | -18.49% | Truist 證券 | → 7 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 08/10/2022 | -53.42% | 派珀·桑德勒 | 4 美元 → 4 美元 | 維護 | 體重不足 |
| 2022 年 6 月 24 日 | -6.84% | 雷蒙德·詹姆 | → 8 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 06/15/2022 | -30.13% | B of A 類證券 | 8 美元 → 6 美元 | 降級 | 買入 → 中性 |
| 05/11/2022 | 16.45% | 瑞士信貸 | 13 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 05/11/2022 | -53.42% | 派珀·桑德勒 | 5 美元 → 4 美元 | 維護 | 體重不足 |
| 05/10/2022 | -6.84% | 花旗集團 | 10 美元 → 8 美元 | 維護 | 買 |
| 05/03/2022 | -6.84% | B of A 類證券 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/20/2022 | 74.67% | 瑞銀（UBS） | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/06/2022 | -41.78% | 派珀·桑德勒 | 8.5 美元 → 5 美元 | 降級 | 中性 → 體重不足 |
| 2022 年 3 月 16 日 | 51.38% | 瑞士信貸 | 15 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 11/10/2021 | 51.38% | 派珀·桑德勒 | 11 美元 → 13 美元 | 維護 | 中立 |
| 2021 年 10 月 20 日 | 97.96% | 傑富瑞集團 | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/19/2021 | 28.09% | 派珀·桑德勒 | → 11 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2021 年 1 月 10 日 | 121.25% | 沃爾夫研究 | → 19 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 09/21/2021 | 132.89% | 花旗集團 | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 10 月 9 日 | 109.6% | Cowen & Co. | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/02/2021 | 109.6% | 瑞士信貸 | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Cano Health (CANO)?
Cano Health（CANO）的目標價格是多少？
The latest price target for Cano Health (NYSE: CANO) was reported by UBS on November 17, 2023. The analyst firm set a price target for $3.75 expecting CANO to fall to within 12 months (a possible -56.33% downside). 9 analyst firms have reported ratings in the last year.
瑞銀於2023年11月17日公佈了Cano Health（紐約證券交易所代碼：CANO）的最新目標股價。該分析公司將目標股價定爲3.75美元，預計CANO將在12個月內降至12個月內（可能下跌56.33％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Cano Health (CANO)?
分析師對Cano Health（CANO）的最新評級是多少？
The latest analyst rating for Cano Health (NYSE: CANO) was provided by UBS, and Cano Health downgraded their sell rating.
瑞銀提供了Cano Health（紐約證券交易所代碼：CANO）的最新分析師評級，Cano Health下調了賣出評級。
When is the next analyst rating going to be posted or updated for Cano Health (CANO)?
Cano Health（CANO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cano Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cano Health was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Cano Health的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Cano Health的最新評級是在2023年11月17日發佈的，因此您應該預計下一個評級將在2024年11月17日左右公佈。
Is the Analyst Rating Cano Health (CANO) correct?
分析師對 Cano Health (CANO) 的評級正確嗎？
While ratings are subjective and will change, the latest Cano Health (CANO) rating was a downgraded with a price target of $12.00 to $3.75. The current price Cano Health (CANO) is trading at is $8.59, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Cano Health（CANO）評級已下調，目標股價爲12.00美元至3.75美元。Cano Health（CANO）目前的交易價格爲8.59美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。